Johnson & Johnson (JNJ) investor relations material

Business performance and growth outlook

• Achieved 7% overall growth, with 10% in the U.S.; excluding STELARA, operational growth reached 17% and 22% in the U.S., with momentum expected to continue into 2026 and beyond.

• Delivered $15.4 billion in Q1, marking the fourth consecutive quarter above $15 billion.

• Targeting 5%-7% compound annual growth rate over the next five years, aiming for the upper end.

• Ten products posted double-digit growth in Q1, with several new launches driving performance.

Immunology product updates

• TREMFYA led IBD market growth with 64% Q1 increase, becoming the induction share leader in IBD and showing strong differentiation, especially in perianal fistulizing Crohn's disease.

• ICOTYDE launch saw rapid prescriber uptake, with 4,500 prescribers and high intent to prescribe; positioned as first-line systemic for psoriasis and advancing in IBD trials.

• JNJ-4804, a co-antibody targeting IL-23 and TNF, showed pronounced effects in refractory IBD, targeting a 1 million patient opportunity.

Oncology pipeline and launches

• RYBREVANT, with new subcutaneous formulation and strong ASCO data, is gaining share in EGFR lung cancer and expanding into head and neck and colorectal cancers.

• ERLEADA demonstrated practice-changing results in high-risk prostate cancer, with double-digit growth and significant runway ahead.

• INLEXZO achieved 82% complete remission in high-risk bladder cancer, with rapid provider adoption post J-code and expansion into broader populations via SunRISe and MoonRISe trials.

• Multiple myeloma strategy centers on foundational use of DARZALEX, with TECVAYLI and CARVYKTI moving BCMA therapies earlier in treatment; tri-specific and in vivo CAR T programs advancing.